Interaction of N-methyl-2-alkenyl-4-quinolones with ATP-dependent MurE ligase of Mycobacterium tuberculosis: Antibacterial activity, molecular docking and inhibition kinetics

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 8, 2011, Pages 1766-1772

  Guzman, Juan David ^a,b   Wube, Abraham ^c   Evangelopoulos, Dimitrios ^a,d   Gupta, Antima ^a   Hüfner, Antje ^c   Basavannacharya, Chandrakala ^a   Rahman, Md Mukhleshur ^b   Thomaschitz, Christina ^c   Bauer, Rudolf ^c   McHugh, Timothy Daniel ^d   Nobeli, Irene ^a   Prieto, Jose M ^b   Gibbons, Simon ^b   Bucar, Franz ^c   Bhakta, Sanjib ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF GRAZ   (Austria)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

4 quinolones; M. tuberculosis; Mur ligase inhibitors

Indexed keywords

4 QUINOLONE DERIVATIVE; ADENOSINE TRIPHOSPHATE; BACTERIAL ENZYME; MURE LIGASE; N METHYL 2 ALKENYL 4 QUINOLONE; UNCLASSIFIED DRUG; URACIL;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BINDING SITE; COLORIMETRY; CONTROLLED STUDY; DILUTION; DRUG BINDING; DRUG INHIBITION; ENZYME ACTIVITY; ESCHERICHIA COLI; GROWTH INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DOCKING; MOLECULAR RECOGNITION; MYCOBACTERIUM; MYCOBACTERIUM BOVIS; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM PHLEI; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PSEUDOMONAS AERUGINOSA; SPECTROSCOPY;

4-QUINOLONES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; ESCHERICHIA COLI; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MYCOBACTERIUM; PEPTIDE SYNTHASES; PROTEIN BINDING; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 79960455669     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr203     Document Type: Article

References (34)

1. Cole ST. Comparative and functional genomics of the Mycobacterium tuberculosis complex. Microbiology 2002; 148: 2919-28.
2. WHO. Global Tuberculosis Control, WHO Report. Geneva: WHO, 2010.
3. DeLeo FR, Otto M, Kreiswirth BN et al. Community-associated meticillinresistant Staphylococcus aureus. Lancet 2010; 375: 1557-68.
4. Howden BP, Ward PB, Charles PGP et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38: 521-8.
5. Ormerod LP. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. Br Med Bull 2005; 73-4: 17-24.
6. Walsh FM, Amyes SGB. Microbiology and drug resistance mechanisms of fully resistant pathogens. Curr Opin Microbiol 2004; 7: 439-44.
7. Velayati AA, Farnia P, Masjedi MR et al. Totally drug-resistant tuberculosis strains: evidence of adaptation at the cellular level. Eur Resp J 2009; 34: 1202-3.
8. Ginsberg AM, Spigelman M. Challenges in tuberculosis drug research and development. Nat Med 2007; 13: 290-4.
9. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007; 70: 461-77.
10. Waksman SA. What is an antibiotic or an antibiotic substance? Mycologia 1947; 39: 565-9.
11. Silver LL. Does the cell wall of bacteria remain a viable source of targets for novel antibiotics? Biochem Pharmacol 2006; 71: 996-1005.
12. Bugg TDH, Braddick D, Dowson CG et al. Bacterial cell wall assembly: still an attractive antibacterial target. Trends Biotechnol 2011; 29: 167-73.
13. Hett EC, Rubin EJ. Bacterial growth and cell division: a mycobacterial perspective. Microbiol Mol Biol Rev 2008; 72: 126-56.
14. Smith CA. Structure, function and dynamics in the mur family of bacterial cell wall ligases. J Mol Biol 2006; 362: 640-55.
15. Bertrand JA, Fanchon E, Martin L et al. 'Open' structures of MurD: domain movements and structural similarities with folylpolyglutamate synthetase. J Mol Biol 2000; 301: 1257-66.
16. Basavannacharya C, Moody P, Munshi T et al. Essential residues for the enzyme activity of ATP-dependent MurE ligase from Mycobacterium tuberculosis. Protein Cell 2010; 1: 1011-22.
17. Basavannacharya C, Robertson G, Munshi T et al. ATP-dependent MurE ligase in Mycobacterium tuberculosis: biochemical and structural characterisation. Tuberculosis 2010; 90: 16-24.
18. Guzman JD, Gupta A, Evangelopoulos D et al. Anti-tubercular screening of natural products from Colombian plants: 3-methoxynordomesticine, an inhibitor of MurE ligase of Mycobacterium tuberculosis. J Antimicrob Chemother 2010; 65: 2101-7.
19. Wube AA, Hüfner A, Thomaschitz C et al. Design, synthesis and antimycobacterial activities of 1-methyl-2-alkenyl-4(1H)-quinolones. Bioorg Med Chem 2011; 19: 567-79.
20. Evangelopoulos D, Bhakta S. Rapid methods for testing inhibitors of mycobacterial growth. In: Antibiotic Resistance Protocols, Methods in Molecular Biology. New York: Humana Press, 2010; 279.
21. Schinkovitz A, Gibbons S, Stavri M et al. Ostruthin: an antimycobacterial coumarin from the roots of Peucedanum ostruthium. Planta Med 2003; 69: 369-71.
22. Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 1995; 8: 127-34.
23. Friesner RA, Banks JL, Murphy RB et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004; 47: 1739-49.
24. Cornish-Bowden A. Fundamentals of Enzyme Kinetics. London: Portland Press, 2004.
25. Adams M, Wube AA, Bucar F et al. Quinolone alkaloids from Evodia rutaecarpa: a potent new group of antimycobacterial compounds. Int J Antimicrob Agents 2005; 26: 262-4.
26. Richardson JF, Reith S. Characterization of a strain of methicillinresistant Staphylococcus aureus (EMRSA-15) by conventional and molecular methods. J Hosp Infect 1993; 25: 45-52.
27. Orme I. Search for new drugs for treatment of tuberculosis. Antimicrob Agents Chemother 2001; 45: 1943-6.
28. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997; 61: 377-92.
29. Xia Y, Yang Z-Y, Morris-Natschke SL et al. Recent advances in the discovery and development of quinolones and analogues as antitumor agents. Curr Med Chem 1999; 6: 179-94.
30. Chu DT, Fernandes PB. Structure-activity relationships of the fluoroquinolones. Antimicrob Agents Chemother 1989; 33: 131-5.
31. Krovat EM, Steindl T, Langer T. Recent advances in docking and scoring. Current Computer-Aided Drug Design 2005; 1: 93-102.
32. Umamaheswari A, Pradhan D, Hemanthkumar M. Virtual screening for potential inhibitors of homology modeled Leptospira interrogans MurD ligase. J Chem Biol 2010; 3: 175-87.
33. Herschlag D. The role of induced fit and conformational changes of enzymes in specificity and catalysis. Bioorg Chem 1988; 16: 62-96.
34. Pettersen EF, Goddard TD, Huang CC et al. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 2004; 25: 1605-12.